AARD Aardvark Therapeutics | 10/23/2026 | Set Price Target | $1.69 | $2.50 | | $0.00 00.00% ROI | |
DFTX Definium Therapeutics | 10/19/2026 | Reiterated Rating | $32.83 | | Outperform | $0.00 00.00% ROI | |
NRIX Nurix Therapeutics | 10/13/2026 | Lower Price Target | $22.16 | $35.00 | Outperform | $0.00 00.00% ROI | |
VRTX Vertex Pharmaceuticals | 10/8/2026 | Boost Price Target | $507.16 | $576.00 | Outperform | $0.00 00.00% ROI | |
INCY Incyte | 10/8/2026 | Boost Price Target | $112.27 | $114.00 | Sector Perform | $0.00 00.00% ROI | |
SRPT Sarepta Therapeutics | 10/8/2026 | Lower Price Target | $17.40 | $17.00 | Sector Perform | $0.00 00.00% ROI | |
REGN Regeneron Pharmaceuticals | 10/8/2026 | Boost Price Target | $730.07 | $810.00 | Sector Perform | $0.00 00.00% ROI | |
GILD Gilead Sciences | 10/8/2026 | Boost Price Target | $145.57 | $126.00 | Sector Perform | $0.00 00.00% ROI | |
BIIB Biogen | 10/8/2026 | Lower Price Target | $219.48 | $256.00 | Outperform | $0.00 00.00% ROI | |
ACAD ACADIA Pharmaceuticals | 10/8/2026 | Lower Price Target | $19.46 | $36.00 | Outperform | $0.00 00.00% ROI | |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
|
PTCT PTC Therapeutics | 10/7/2026 | Lower Price Target | $63.70 | $75.00 | Sector Perform | $0.00 00.00% ROI | |
REGN Regeneron Pharmaceuticals | 9/29/2026 | Reiterated Rating | $752.25 | $737.00 | Sector Perform | $0.00 00.00% ROI | |
AARD Aardvark Therapeutics | 9/24/2026 | Reiterated Rating | $5.50 | $6.00 | Sector Perform | $0.00 00.00% ROI | |
LKFT Lakefront Biotherapeutics American Depositary Shares | 9/23/2026 | Upgrade | $30.19 | $45.00 | Outperform | $0.00 00.00% ROI | |
INCY Incyte | 9/22/2026 | Reiterated Rating | $125.09 | $109.00 | Sector Perform | $0.00 00.00% ROI | |
XENE Xenon Pharmaceuticals | 9/18/2026 | Lower Price Target | $41.17 | $70.00 | Outperform | $0.00 00.00% ROI | |
DFTX Definium Therapeutics | 9/11/2026 | Reiterated Rating | $38.60 | $66.00 | Outperform | $0.00 00.00% ROI | |
BCRX BioCryst Pharmaceuticals | 9/10/2026 | Downgrade | $8.81 | $11.00 | Sector Perform | $0.00 00.00% ROI | |
EVMN Evommune | 9/9/2026 | Lower Price Target | $11.25 | $21.00 | Outperform | $0.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 9/8/2026 | Reiterated Rating | $156.07 | $198.00 | Outperform | $0.00 00.00% ROI | |
ATTO Attovia Therapeutics | 8/31/2026 | Initiated Coverage | $20.70 | $45.00 | Outperform | $0.00 00.00% ROI | |
ATTO Attovia Therapeutics | 8/30/2026 | Upgrade | $21.40 | | Moderate Buy | $0.00 00.00% ROI | |
BIIB Biogen | 8/25/2026 | Boost Price Target | $218.12 | $260.00 | Outperform | $0.00 00.00% ROI | |
DFTX Definium Therapeutics | 8/13/2026 | Boost Price Target | $44.46 | $66.00 | Outperform | $0.00 00.00% ROI | |
PHVS Pharvaris | 8/13/2026 | Boost Price Target | $34.56 | $52.00 | Outperform | $0.00 00.00% ROI | |
LKFT Lakefront Biotherapeutics American Depositary Shares | 8/11/2026 | Lower Price Target | $27.96 | $26.00 | Sector Perform | $0.00 00.00% ROI | |
NRIX Nurix Therapeutics | 8/10/2026 | Boost Price Target | $25.57 | $36.00 | Outperform | $0.00 00.00% ROI | |
XENE Xenon Pharmaceuticals | 8/7/2026 | Lower Price Target | $63.64 | $81.00 | Outperform | $0.00 00.00% ROI | |
EVMN Evommune | 8/7/2026 | Lower Price Target | $14.20 | $29.00 | Outperform | $0.00 00.00% ROI | |
BCRX BioCryst Pharmaceuticals | 8/6/2026 | Lower Price Target | $9.42 | $13.00 | Outperform | $0.00 00.00% ROI | |
ACAD ACADIA Pharmaceuticals | 8/5/2026 | Boost Price Target | $28.32 | $37.00 | Outperform | $0.00 00.00% ROI | |
GILD Gilead Sciences | 8/5/2026 | Boost Price Target | $130.70 | $123.00 | Sector Perform | $0.00 00.00% ROI | |
CTNM Contineum Therapeutics | 7/31/2026 | Boost Price Target | $15.27 | $23.00 | Outperform | $0.00 00.00% ROI | |
REGN Regeneron Pharmaceuticals | 7/31/2026 | Boost Price Target | $763.17 | $737.00 | Sector Perform | $0.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 7/31/2026 | Boost Price Target | $166.77 | $198.00 | Outperform | $0.00 00.00% ROI | |
BIIB Biogen | 7/30/2026 | Lower Price Target | $205.31 | $240.00 | Outperform | $0.00 00.00% ROI | |
INCY Incyte | 7/29/2026 | Boost Price Target | $127.16 | $109.00 | Sector Perform | $0.00 00.00% ROI | |
KYMR Kymera Therapeutics | 7/13/2026 | Downgrade | $119.35 | $115.00 | Sector Perform | $0.00 00.00% ROI | |
NMRA Neumora Therapeutics | 7/13/2026 | Lower Price Target | $1.62 | $5.00 | Outperform | $0.00 00.00% ROI | |
NRIX Nurix Therapeutics | 7/10/2026 | Boost Price Target | $23.97 | $33.00 | Outperform | $0.00 00.00% ROI | |
Why tech stocks are dead (Ad) AI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the big tech names pouring billions into data centers.
Walmart's $24 million satellite network, AMR's Sabre system, and Capital One's 36,114 pricing tests all prove the same thing: compute has always been business's biggest moat, and it's about to get cheaper than ever.
Porter Stansberry says one overlooked, government-protected sector is positioned to absorb this near-free compute boom and could become the next Magnificent 7. Watch Porter Stansberry's broadcast to see which sector could lead next |
VRTX Vertex Pharmaceuticals | 7/7/2026 | Boost Price Target | $529.59 | $570.00 | Outperform | $0.00 00.00% ROI | |
PTCT PTC Therapeutics | 7/7/2026 | Boost Price Target | $85.44 | $85.00 | Sector Perform | $0.00 00.00% ROI | |
INCY Incyte | 7/7/2026 | Boost Price Target | $115.62 | $99.00 | Sector Perform | $0.00 00.00% ROI | |
BIIB Biogen | 7/7/2026 | Boost Price Target | $208.46 | $242.00 | Outperform | $0.00 00.00% ROI | |
ACAD ACADIA Pharmaceuticals | 7/7/2026 | Boost Price Target | $25.77 | $36.00 | Outperform | $0.00 00.00% ROI | |
REGN Regeneron Pharmaceuticals | 7/7/2026 | Lower Price Target | $668.88 | $696.00 | Sector Perform | $0.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 7/7/2026 | Boost Price Target | $178.11 | $195.00 | Outperform | $0.00 00.00% ROI | |
GILD Gilead Sciences | 7/7/2026 | Lower Price Target | $134.71 | $120.00 | Sector Perform | $0.00 00.00% ROI | |
BCRX BioCryst Pharmaceuticals | 7/7/2026 | Boost Price Target | $10.19 | $14.00 | Outperform | $0.00 00.00% ROI | |
GILD Gilead Sciences | 6/8/2026 | Reiterated Rating | $129.17 | | Sector Perform | $0.00 00.00% ROI | |
APGE Apogee Therapeutics | 6/8/2026 | Boost Price Target | $86.92 | $97.00 | Sector Perform | $0.00 00.00% ROI | |
GILD Gilead Sciences | 6/1/2026 | Reiterated Rating | $134.43 | $122.00 | Overweight | $0.00 00.00% ROI | |
GILD Gilead Sciences | 6/1/2026 | Upgrade | $131.10 | | Moderate Buy | $0.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 5/29/2026 | Boost Price Target | $157.47 | $183.00 | Outperform | $0.00 00.00% ROI | |
BIIB Biogen | 5/27/2026 | Boost Price Target | $193.08 | $227.00 | Outperform | $0.00 00.00% ROI | |
REGN Regeneron Pharmaceuticals | 5/18/2026 | Lower Price Target | $623.32 | $707.00 | Sector Perform | $0.00 00.00% ROI | |
GILD Gilead Sciences | 5/8/2026 | Lower Price Target | $130.55 | $122.00 | Sector Perform | $0.00 00.00% ROI | |
PTCT PTC Therapeutics | 5/8/2026 | Boost Price Target | $79.08 | $82.00 | Sector Perform | $0.00 00.00% ROI | |
XENE Xenon Pharmaceuticals | 5/8/2026 | Boost Price Target | $55.89 | $82.00 | Outperform | $0.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 5/6/2026 | Boost Price Target | $144.90 | $180.00 | Outperform | $0.00 00.00% ROI | |
VRTX Vertex Pharmaceuticals | 5/5/2026 | Boost Price Target | $429.85 | $543.00 | Outperform | $0.00 00.00% ROI | |
BIIB Biogen | 4/30/2026 | Boost Price Target | $191.32 | $222.00 | Outperform | $0.00 00.00% ROI | |
REGN Regeneron Pharmaceuticals | 4/30/2026 | Lower Price Target | $707.09 | $762.00 | Sector Perform | $0.00 00.00% ROI | |
BIIB Biogen | 4/29/2026 | Boost Price Target | $191.58 | $222.00 | Outperform | $0.00 00.00% ROI | |
DMRA Damora Therapeutics, Inc. Common Stock | 4/24/2026 | Initiated Coverage | $25.42 | $40.00 | Outperform | $0.00 00.00% ROI | |
DMRA Damora Therapeutics, Inc. Common Stock | 4/23/2026 | Upgrade | $24.75 | | Moderate Buy | $0.00 00.00% ROI | |
EVMN Evommune | 4/10/2026 | Reiterated Rating | $27.56 | $48.00 | Outperform | $0.00 00.00% ROI | |
PHVS Pharvaris | 4/6/2026 | Lower Price Target | $28.56 | $51.00 | Outperform | $0.00 00.00% ROI | |
PHVS Pharvaris | 3/9/2026 | Initiated Coverage | $26.63 | $52.00 | Outperform | $0.00 00.00% ROI | |
APGE Apogee Therapeutics | 3/2/2026 | Lower Price Target | $70.92 | $82.00 | Sector Perform | $0.00 00.00% ROI | |
AARD Aardvark Therapeutics | 3/2/2026 | Downgrade | $12.49 | $6.00 | Sector Perform | $0.00 00.00% ROI | |
REGN Regeneron Pharmaceuticals | 3/2/2026 | Boost Price Target | $784.09 | $765.00 | Sector Perform | $0.00 00.00% ROI | |
MLTX MoonLake Immunotherapeutics | 3/2/2026 | Boost Price Target | $17.69 | $13.00 | Sector Perform | $0.00 00.00% ROI | |
KYMR Kymera Therapeutics | 2/26/2026 | Reiterated Rating | $91.56 | $108.00 | Outperform | $0.00 00.00% ROI | |
ACAD ACADIA Pharmaceuticals | 2/26/2026 | Lower Price Target | $24.82 | $30.00 | Outperform | $0.00 00.00% ROI | |
LKFT Lakefront Biotherapeutics American Depositary Shares | 2/24/2026 | Boost Price Target | $34.36 | $33.00 | Sector Perform | $0.00 00.00% ROI | |
PTCT PTC Therapeutics | 2/20/2026 | Lower Price Target | $69.90 | $82.00 | Sector Perform | $0.00 00.00% ROI | |
MLTX MoonLake Immunotherapeutics | 2/20/2026 | Boost Price Target | $17.86 | $12.00 | Sector Perform | $0.00 00.00% ROI | |
PRTA Prothena | 2/20/2026 | Boost Price Target | $8.83 | $12.00 | Sector Perform | $0.00 00.00% ROI | |
VRTX Vertex Pharmaceuticals | 2/13/2026 | Lower Price Target | $496.69 | $541.00 | Outperform | $0.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 2/12/2026 | Lower Price Target | $126.01 | $177.00 | Outperform | $0.00 00.00% ROI | |
GILD Gilead Sciences | 2/11/2026 | Boost Price Target | $156.39 | $118.00 | Sector Perform | $0.00 00.00% ROI | |
INCY Incyte | 2/11/2026 | Lower Price Target | $98.59 | $92.00 | Sector Perform | $0.00 00.00% ROI | |
BIIB Biogen | 2/9/2026 | Boost Price Target | $201.18 | $233.00 | Outperform | $0.00 00.00% ROI | |
ACAD ACADIA Pharmaceuticals | 2/3/2026 | Lower Price Target | $26.13 | $31.00 | Outperform | $0.00 00.00% ROI | |
BCRX BioCryst Pharmaceuticals | 1/30/2026 | Lower Price Target | $6.44 | $13.00 | Outperform | $0.00 00.00% ROI | |
NRIX Nurix Therapeutics | 1/29/2026 | Boost Price Target | $17.60 | $30.00 | Outperform | $0.00 00.00% ROI | |
GHRS GH Research | 1/23/2026 | Boost Price Target | $16.46 | $40.00 | Outperform | $0.00 00.00% ROI | |
DFTX Definium Therapeutics | 1/23/2026 | Boost Price Target | $17.29 | $36.00 | Outperform | $0.00 00.00% ROI | |
APGE Apogee Therapeutics | 1/22/2026 | Downgrade | $81.91 | $83.00 | Sector Perform | $0.00 00.00% ROI | |
Financial legend: “This is bad, really bad...” (Ad) Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit.
Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks. See Martin Weiss's full warning before this risk spreads further |
VRTX Vertex Pharmaceuticals | 1/22/2026 | Upgrade | $461.14 | $546.00 | Outperform | $0.00 00.00% ROI | |
GILD Gilead Sciences | 1/20/2026 | Boost Price Target | $124.91 | $103.00 | Sector Perform | $0.00 00.00% ROI | |
BIIB Biogen | 1/13/2026 | Reiterated Rating | $178.30 | | Outperform | $0.00 00.00% ROI | |
GILD Gilead Sciences | 1/8/2026 | Lower Price Target | $121.35 | $100.00 | Sector Perform | $0.00 00.00% ROI | |
SRPT Sarepta Therapeutics | 1/8/2026 | Boost Price Target | $21.31 | $18.00 | Sector Perform | $0.00 00.00% ROI | |
APGE Apogee Therapeutics | 1/6/2026 | Reiterated Rating | $78.59 | | Outperform | $0.00 00.00% ROI | |
KYMR Kymera Therapeutics | 12/16/2025 | Boost Price Target | $85.68 | $103.00 | Outperform | $0.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 12/8/2025 | Boost Price Target | $159.46 | $180.00 | Outperform | $0.00 00.00% ROI | |
PTCT PTC Therapeutics | 12/1/2025 | Downgrade | $85.99 | $91.00 | Sector Perform | $0.00 00.00% ROI | |
NMRA Neumora Therapeutics | 12/1/2025 | Upgrade | $2.26 | $7.00 | Outperform | $0.00 00.00% ROI | |
SION Sionna Therapeutics | 12/1/2025 | Reiterated Rating | $43.57 | $24.00 | Underperform | $0.00 00.00% ROI | |
CTNM Contineum Therapeutics | 11/21/2025 | Lower Price Target | $11.08 | $22.00 | Outperform | $0.00 00.00% ROI | |
CDTX Cidara Therapeutics | 11/17/2025 | Downgrade | $217.78 | | Sector Perform | $0.00 00.00% ROI | |
AARD Aardvark Therapeutics | 11/14/2025 | Lower Price Target | $10.86 | $18.00 | Outperform | $0.00 00.00% ROI | |
CRBP Corbus Pharmaceuticals | 11/13/2025 | Lower Price Target | $11.09 | $53.00 | Outperform | $0.00 00.00% ROI | |
PRTA Prothena | 11/7/2025 | Boost Price Target | $10.15 | $11.00 | Sector Perform | $0.00 00.00% ROI | |
DFTX Definium Therapeutics | 11/7/2025 | Lower Price Target | $11.26 | $20.00 | Outperform | $0.00 00.00% ROI | |
LKFT Lakefront Biotherapeutics American Depositary Shares | 11/7/2025 | Boost Price Target | $31.38 | $32.00 | Sector Perform | $0.00 00.00% ROI | |
CDTX Cidara Therapeutics | 11/7/2025 | Boost Price Target | $99.95 | $145.00 | Outperform | $0.00 00.00% ROI | |
ACAD ACADIA Pharmaceuticals | 11/6/2025 | Lower Price Target | $21.35 | $32.00 | Outperform | $0.00 00.00% ROI | |
PTCT PTC Therapeutics | 11/5/2025 | Boost Price Target | $72.90 | $82.00 | Outperform | $0.00 00.00% ROI | |
XENE Xenon Pharmaceuticals | 11/4/2025 | Boost Price Target | $39.54 | $58.00 | Outperform | $0.00 00.00% ROI | |
VRTX Vertex Pharmaceuticals | 11/4/2025 | Lower Price Target | $430.41 | $415.00 | Sector Perform | $0.00 00.00% ROI | |
KPTI Karyopharm Therapeutics | 11/4/2025 | Lower Price Target | $5.66 | $19.00 | Outperform | $0.00 00.00% ROI | |
APGE Apogee Therapeutics | 11/3/2025 | Boost Price Target | $57.13 | $70.00 | Outperform | $0.00 00.00% ROI | |
BIIB Biogen | 10/31/2025 | Lower Price Target | $149.61 | $210.00 | Outperform | $0.00 00.00% ROI | |
GILD Gilead Sciences | 10/31/2025 | Boost Price Target | $120.73 | $105.00 | Sector Perform | $0.00 00.00% ROI | |
INCY Incyte | 10/29/2025 | Boost Price Target | $89.19 | $84.00 | Sector Perform | $0.00 00.00% ROI | |
REGN Regeneron Pharmaceuticals | 10/29/2025 | Boost Price Target | $654.96 | $708.00 | Sector Perform | $0.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 10/29/2025 | Boost Price Target | $139.82 | $160.00 | Outperform | $0.00 00.00% ROI | |
LKFT Lakefront Biotherapeutics American Depositary Shares | 10/22/2025 | Boost Price Target | $32.33 | $28.00 | Sector Perform | $00.00 00.00% ROI | |
BIIB Biogen | 10/8/2025 | Lower Price Target | $152.21 | $217.00 | Outperform | $000.00 00.00% ROI | |
GILD Gilead Sciences | 10/8/2025 | Boost Price Target | $116.78 | $100.00 | Sector Perform | $000.00 00.00% ROI | |
SRPT Sarepta Therapeutics | 10/8/2025 | Boost Price Target | $24.02 | $16.00 | Sector Perform | $00.00 00.00% ROI | |
MLTX MoonLake Immunotherapeutics | 9/29/2025 | Reiterated Rating | $6.86 | $10.00 | Sector Perform | $00.00 00.00% ROI | |
APGE Apogee Therapeutics | 9/25/2025 | Initiated Coverage | $38.42 | $60.00 | Outperform | $000.00 00.00% ROI | |
CDTX Cidara Therapeutics | 9/24/2025 | Set Price Target | $88.16 | $137.00 | Outperform | $0.00 00.00% ROI | |
INCY Incyte | 9/24/2025 | Boost Price Target | $84.54 | $81.00 | Sector Perform | $000.00 00.00% ROI | |
KYMR Kymera Therapeutics | 9/16/2025 | Initiated Coverage | $47.28 | $70.00 | Outperform | $000.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 9/5/2025 | Boost Price Target | $143.76 | $149.00 | Outperform | $000.00 00.00% ROI | |
SION Sionna Therapeutics | 9/3/2025 | Initiated Coverage | $25.39 | $22.00 | Sector Perform | $0.00 00.00% ROI | |
XENE Xenon Pharmaceuticals | 9/2/2025 | Reiterated Rating | $39.12 | $55.00 | Outperform | $00.00 00.00% ROI | |
AARD Aardvark Therapeutics | 8/14/2025 | Lower Price Target | $11.44 | $19.00 | Outperform | $0.00 00.00% ROI | |
XENE Xenon Pharmaceuticals | 8/12/2025 | Lower Price Target | $36.96 | $55.00 | Outperform | $00.00 00.00% ROI | |
PTCT PTC Therapeutics | 8/8/2025 | Reiterated Rating | $46.87 | $63.00 | Outperform | $00.00 00.00% ROI | |
ETNB 89BIO | 8/8/2025 | Lower Price Target | $8.92 | $11.00 | Sector Perform | $0.00 00.00% ROI | |
GILD Gilead Sciences | 8/8/2025 | Boost Price Target | $119.21 | $98.00 | Sector Perform | $000.00 00.00% ROI | |
ACAD ACADIA Pharmaceuticals | 8/7/2025 | Boost Price Target | $23.84 | $40.00 | Outperform | $00.00 00.00% ROI | |
VRTX Vertex Pharmaceuticals | 8/5/2025 | Lower Price Target | $389.93 | $405.00 | Sector Perform | $000.00 00.00% ROI | |
PRTA Prothena | 8/5/2025 | Lower Price Target | $7.28 | $10.00 | Sector Perform | $0.00 00.00% ROI | |
Trump’s Plan To Cheat History (Ad) China has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and payment networks that bypass the dollar entirely.
Since the Federal Reserve opened in 1913, the dollar has lost most of its purchasing power. Porter Stansberry argues a new monetary order is forming around AI infrastructure, chips and energy, pointing to stocks like Vertiv, GE Vernova and Arista Networks that have surged hundreds of percent in recent years. Watch Porter Stansberry's full interview and see his top pick now |
REGN Regeneron Pharmaceuticals | 8/4/2025 | Boost Price Target | $569.71 | $695.00 | Sector Perform | $000.00 00.00% ROI | |
BIIB Biogen | 8/1/2025 | Boost Price Target | $126.28 | $219.00 | Outperform | $000.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 7/31/2025 | Lower Price Target | $129.41 | $144.00 | Outperform | $000.00 00.00% ROI | |
INCY Incyte | 7/30/2025 | Boost Price Target | $77.88 | $72.00 | Sector Perform | $000.00 00.00% ROI | |
SRPT Sarepta Therapeutics | 7/17/2025 | Lower Price Target | $21.46 | $23.00 | Sector Perform | $00.00 00.00% ROI | |
BCRX BioCryst Pharmaceuticals | 6/30/2025 | Reiterated Rating | $9.23 | $13.00 | Outperform | $0.00 00.00% ROI | |
BIIB Biogen | 6/25/2025 | Set Price Target | $126.16 | $213.00 | Outperform | $000.00 00.00% ROI | |
CDTX Cidara Therapeutics | 6/24/2025 | Upgrade | $49.86 | $75.00 | Moderate Buy | $0.00 00.00% ROI | |
ACAD ACADIA Pharmaceuticals | 6/23/2025 | Boost Price Target | $22.12 | $38.00 | Outperform | $00.00 00.00% ROI | |
VRTX Vertex Pharmaceuticals | 6/17/2025 | Lower Price Target | $448.47 | $420.00 | Sector Perform | $000.00 00.00% ROI | |
REGN Regeneron Pharmaceuticals | 5/27/2025 | Reiterated Rating | $599.20 | $662.00 | Sector Perform | $000.00 00.00% ROI | |
CTNM Contineum Therapeutics | 5/15/2025 | Reiterated Rating | $3.72 | $31.00 | Outperform | $00.00 00.00% ROI | |
KPTI Karyopharm Therapeutics | 5/13/2025 | Lower Price Target | $5.40 | $33.00 | Outperform | $0.00 00.00% ROI | |
XENE Xenon Pharmaceuticals | 5/13/2025 | Lower Price Target | $29.93 | $55.00 | Outperform | $00.00 00.00% ROI | |
CRBP Corbus Pharmaceuticals | 5/7/2025 | Lower Price Target | $6.34 | $58.00 | Outperform | $00.00 00.00% ROI | |
VRTX Vertex Pharmaceuticals | 5/6/2025 | Boost Price Target | $434.64 | $423.00 | Sector Perform | $000.00 00.00% ROI | |
BCRX BioCryst Pharmaceuticals | 5/6/2025 | Reiterated Rating | $10.40 | $13.00 | Outperform | $0.00 00.00% ROI | |
BIIB Biogen | 5/2/2025 | Lower Price Target | $122.38 | $205.00 | Outperform | $000.00 00.00% ROI | |
INCY Incyte | 4/30/2025 | Boost Price Target | $61.11 | $67.00 | Sector Perform | $00.00 00.00% ROI | |
REGN Regeneron Pharmaceuticals | 4/30/2025 | Lower Price Target | $586.51 | $943.00 | Outperform | $000.00 00.00% ROI | |
LEGN Legend Biotech | 4/22/2025 | Reiterated Rating | $33.48 | $84.00 | Outperform | $00.00 00.00% ROI | |
BIIB Biogen | 4/22/2025 | Boost Price Target | $117.63 | $225.00 | Outperform | $000.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 4/14/2025 | Upgrade | $90.87 | $137.00 | Outperform | $000.00 00.00% ROI | |
BCRX BioCryst Pharmaceuticals | 4/11/2025 | Reiterated Rating | $6.55 | $11.00 | Outperform | $0.00 00.00% ROI | |
VRTX Vertex Pharmaceuticals | 4/1/2025 | Boost Price Target | $487.06 | $420.00 | Sector Perform | $000.00 00.00% ROI | |
SRPT Sarepta Therapeutics | 3/31/2025 | Downgrade | $70.41 | $87.00 | Sector Perform | $00.00 00.00% ROI | |
MLTX MoonLake Immunotherapeutics | 3/18/2025 | Initiated Coverage | $38.67 | $67.00 | Outperform | $00.00 00.00% ROI | |
AARD Aardvark Therapeutics | 3/10/2025 | Initiated Coverage | $10.13 | $21.00 | Outperform | $0.00 00.00% ROI | |
GHRS GH Research | 3/7/2025 | Initiated Coverage | $10.55 | $31.00 | Outperform | $00.00 00.00% ROI | |
SRPT Sarepta Therapeutics | 2/27/2025 | Lower Price Target | $107.24 | $161.00 | Outperform | $00.00 00.00% ROI | |
BCRX BioCryst Pharmaceuticals | 2/25/2025 | Reiterated Rating | $8.11 | $11.00 | Outperform | $0.00 00.00% ROI | |
PRTA Prothena | 2/21/2025 | Lower Price Target | $15.61 | $20.00 | Sector Perform | $0.00 00.00% ROI | |
VRTX Vertex Pharmaceuticals | 2/20/2025 | Boost Price Target | $475.68 | $408.00 | Sector Perform | $000.00 00.00% ROI | |
KPTI Karyopharm Therapeutics | 2/20/2025 | Reiterated Rating | $9.41 | $45.00 | Outperform | $0.00 00.00% ROI | |
BIIB Biogen | 2/13/2025 | Lower Price Target | $135.56 | $225.00 | Outperform | $000.00 00.00% ROI | |
GILD Gilead Sciences | 2/12/2025 | Boost Price Target | $103.52 | $90.00 | Sector Perform | $000.00 00.00% ROI | |
INCY Incyte | 2/11/2025 | Lower Price Target | $68.30 | $68.00 | Sector Perform | $000.00 00.00% ROI | |
VRTX Vertex Pharmaceuticals | 2/11/2025 | Boost Price Target | $459.15 | $407.00 | Sector Perform | $000.00 00.00% ROI | |
PLRX Pliant Therapeutics | 2/10/2025 | Downgrade | $7.79 | $4.00 | Sector Perform | $0.00 00.00% ROI | |
KPTI Karyopharm Therapeutics | 2/10/2025 | Reiterated Rating | $9.77 | $45.00 | Outperform | $0.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 2/7/2025 | Lower Price Target | $122.00 | $148.00 | Sector Perform | $000.00 00.00% ROI | |
GILD Gilead Sciences | 2/3/2025 | Reiterated Rating | $99.12 | $84.00 | Sector Perform | $000.00 00.00% ROI | |
AXSM Axsome Therapeutics | 1/29/2025 | Reiterated Rating | $104.53 | $139.00 | Outperform | $000.00 00.00% ROI | |